Abstract
The key regular functions of microRNAs (miRNAs) were only discovered a few years ago, when it became evident that miRNAs play important roles in gene regulation. Today, more than 700 miRNAs have been identified from the human genome. Because of their regulatory functions in transcription, signal transduction, cell cycle regulation, proliferation, cell growth, apoptosis, cell metabolism and neurogenesis, malfunctioning miRNAs have been suggested to affect a number of diseases. Indeed, absence of miRNAs or their mutations has been associated with various types of cancers and other diseases such as neurodegenerative, autoimmune, cardiovascular, infectious, metabolic and oncologic diseases. This has been confirmed by genetic analysis of patient samples. The disease association has attracted potential diagnostic and therapeutic applications of miRNAs. A significant issue to achieve successful therapy is the delivery of miRNAs as problems of targeted and long-lasting presence of miRNA exist. Different approaches have included the modification of miRNAs and the use of viral delivery vectors.
Keywords: Gene regulation, miRNAs as diagnostics, therapeutic miRNAs, delivery of miRNAs
Current Drug Discovery Technologies
Title: Micro-RNA in Disease and Gene Therapy
Volume: 8 Issue: 2
Author(s): Kenneth Lundstrom
Affiliation:
Keywords: Gene regulation, miRNAs as diagnostics, therapeutic miRNAs, delivery of miRNAs
Abstract: The key regular functions of microRNAs (miRNAs) were only discovered a few years ago, when it became evident that miRNAs play important roles in gene regulation. Today, more than 700 miRNAs have been identified from the human genome. Because of their regulatory functions in transcription, signal transduction, cell cycle regulation, proliferation, cell growth, apoptosis, cell metabolism and neurogenesis, malfunctioning miRNAs have been suggested to affect a number of diseases. Indeed, absence of miRNAs or their mutations has been associated with various types of cancers and other diseases such as neurodegenerative, autoimmune, cardiovascular, infectious, metabolic and oncologic diseases. This has been confirmed by genetic analysis of patient samples. The disease association has attracted potential diagnostic and therapeutic applications of miRNAs. A significant issue to achieve successful therapy is the delivery of miRNAs as problems of targeted and long-lasting presence of miRNA exist. Different approaches have included the modification of miRNAs and the use of viral delivery vectors.
Export Options
About this article
Cite this article as:
Lundstrom Kenneth, Micro-RNA in Disease and Gene Therapy, Current Drug Discovery Technologies 2011; 8 (2) . https://dx.doi.org/10.2174/157016311795563857
DOI https://dx.doi.org/10.2174/157016311795563857 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Respiratory Syncytial Virus (RSV) Prevention and Treatment: Past, Present, and Future
Cardiovascular & Hematological Agents in Medicinal Chemistry Endothelin-1 and Endothelin Converting Enzyme-1 in Human Atherosclerosis - Novel Targets for Pharmacotherapy in Atherosclerosis
Current Vascular Pharmacology The Role of PPARs in Pathological Cardiac Hypertrophy and Heart Failure
Current Pharmaceutical Design Hypertension and Angiogenesis
Current Pharmaceutical Design Role of the heme oxygenase-adiponectin-atrial natriuretic peptide axis in renal function
Current Pharmaceutical Design Mitochondrial Involvement in Psychiatric Illness in Adults
Current Psychiatry Reviews Regulation of Self-Reactive T Cells by Human Immunoglobulins- Implications for Multiple Sclerosis Therapy
Current Pharmaceutical Design A Mini-Review on Cardiovascular and Hematological Complications of COVID-19
Coronaviruses Intra-Renal Hemodynamic Changes After Habitual Physical Activity in Patients with Chronic Kidney Disease
Current Pharmaceutical Design Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety A Palliative Care Approach to the Advanced Heart Failure Patient
Current Cardiology Reviews Nanocarriers Assisted siRNA Gene Therapy for the Management of Cardiovascular Disorders
Current Pharmaceutical Design Effectiveness of Resveratrol Against Cardiovascular Disease
Mini-Reviews in Organic Chemistry Hypertension in Type 2 Diabetes Mellitus: Do We Need to Redefine the Role of Sulfonylureas?
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Lost in Translation: What is Limiting Cardiomyoplasty and Can Tissue Engineering Help?
Current Stem Cell Research & Therapy MicroRNA-130a Regulation of Desmocollin 2 in a Novel Model of Arrhythmogenic Cardiomyopathy
MicroRNA Molecular Replacement in Cancer Therapy: Reversing Cancer Metabolic and Mitochondrial Dysfunction, Fatigue and the Adverse Effects of Cancer Therapy
Current Cancer Therapy Reviews New Developments in Anthracycline-Induced Cardiotoxicity
Current Medicinal Chemistry Recent Advances in Antiarrhythmic Drug Treatment of Atrial Fibrillation
Recent Patents on Cardiovascular Drug Discovery Protectors of the Mitochondrial Permeability Transition Pore Activated by Iron and Doxorubicin
Current Cancer Drug Targets